hotspot -WSS

hotspot

author：comprehensive 2025-09-29 21:27:38 - browse：71

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

entertainment

leisure time

WSS

ProMED, early warning system on disease outbreaks, in peril

Gilgo Beach: Police identify another victim in serial killing investigation

Dramatically reducing cancer deaths requires the PASTEUR Act

Who gets to use the title 'doctor'?

Argenx drug significantly slows progression of nerve disorder

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

explore

hotspot

knowledge

Cancer drug shortages should be causing more outrage

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Medical records are filled with copy

Mike Pence clashes with Tucker Carlson in Iowa

New air purifier tech could be key to improving indoor air quality

Influencer to be charged after chaos erupts in New York City's Union Square

Bright Health sells Medicare Advantage business to Molina

Stem cell clinics for heart failure: buyer be wary

focus

Stem cell clinics for heart failure: buyer be wary

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

For BCIs, commercial hurdles may be bigger than scientific ones

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Congress likely to miss an opportunity to fix drug shortages issue

explore

entertainment

leisure time

knowledge